Format

Send to

Choose Destination
Ann Hematol. 2018 Dec;97(12):2437-2445. doi: 10.1007/s00277-018-3449-8. Epub 2018 Aug 1.

Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German Tumour Registry Lymphatic Neoplasms.

Author information

1
Joint Outpatient-Centre for Oncology, Frankfurt a. M., Germany.
2
Joint Outpatient-Centre for Haematology and Oncology, Leipzig, Germany.
3
Joint Outpatient-Centre for Haematology and Oncology, Nordhorn, Germany.
4
Joint Outpatient-Centre for Haematology and Oncology, Aschaffenburg, Germany.
5
Medical Department, iOMEDICO, Freiburg, Germany.
6
Clinical Epidemiology and Health Economics, iOMEDICO, Freiburg, Germany.
7
Outpatient-Centre for Interdisciplinary Oncology and Haematology, Wirthstrasse 11c, 79110, Freiburg, Germany. manuskript@onkologie-freiburg.de.

Abstract

Despite increasing treatment options, multiple myeloma (MM) remains incurable for most patients. Data on improvement of outcomes are derived from selected patient populations enrolled in clinical trials and might not be conferrable to all patients. Therefore, we assessed the trial eligibility, sequential treatment, and survival of non-transplant patients with MM treated in German routine care. The prospective clinical cohort study TLN (Tumour Registry Lymphatic Neoplasms) recruited 285 non-transplant patients with symptomatic MM at start of first-line treatment in 84 centres from 2009 to 2011. Demographic and clinical data were collected until August 2016. Trial-ineligibility was determined by presence of at least one of the common exclusion criteria: heart/renal failure, liver/renal diseases, polyneuropathy, HIV positivity. All other patients were considered potentially trial-eligible. Thirty percent of the patients in our study were classified as trial-ineligible. Median first-line progression-free survival (PFS) and overall survival (OS) of trial-ineligible patients were inferior to that of potentially trial-eligible patients: PFS 16.2 months (95% CI (confidence interval) 11.1-20.4) vs. 27.3 months (95% CI 23.3-33.0); OS 34.2 months (95% CI 21.6-48.1) vs. 58.6 months (95% CI 48.6-64.4). A high percentage of non-transplant patients with MM in German routine care would be ineligible for participation in clinical trials. Despite similar treatment algorithms, their first-line PFS and OS were shorter than those of potentially trial-eligible patients; the survival data of the latter were similar to results from clinical trials. Physicians should be aware of the fact that results from clinical trials may not mirror "real world" patient outcomes when discussing outcome expectations with patients. Trial registration: Clinicaltrials.gov identifier: NCT00889798.

KEYWORDS:

Multiple myeloma; Outcome assessment; Outpatients; Registries

PMID:
30069704
PMCID:
PMC6208687
DOI:
10.1007/s00277-018-3449-8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center